CD47, SIRPa, Fc receptor, antibody engineering, phagocytosis, macrophage, cancer immunotherapy, innate immunity
CD40, Fc Receptor, non-muscle invasive bladder cancer, immune triads, tertiary lymphoid structures, dendritic cells, BCG, cancer immunotherapy, antibody, clinical trial